ArticleRheumatology and therapy2023

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).

Alan Kivitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.